AIMMUNE THERAPEUTICS INC's ticker is AIMT and the CUSIP is 00900T107. A total of 193 filers reported holding AIMMUNE THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is 1.23 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2020 | $53,357,000 | -3.9% | 3,193,117 | -17.1% | 1.16% | -35.5% |
| Q1 2020 | $55,531,000 | -46.2% | 3,851,000 | +24.9% | 1.80% | -38.2% |
| Q4 2019 | $103,221,000 | +59.8% | 3,084,000 | 0.0% | 2.91% | +36.3% |
| Q3 2019 | $64,579,000 | +11.8% | 3,084,000 | +11.1% | 2.13% | +21.5% |
| Q2 2019 | $57,776,000 | +31.8% | 2,775,000 | +41.4% | 1.76% | +16.4% |
| Q1 2019 | $43,851,000 | +5.4% | 1,962,000 | +12.8% | 1.51% | -18.1% |
| Q4 2018 | $41,597,000 | -12.3% | 1,739,000 | 0.0% | 1.84% | +5.7% |
| Q3 2018 | $47,440,000 | +8.9% | 1,739,000 | +7.3% | 1.74% | -3.7% |
| Q2 2018 | $43,562,000 | -12.5% | 1,620,000 | +3.5% | 1.81% | -22.5% |
| Q1 2018 | $49,813,000 | +7.4% | 1,564,983 | +27.6% | 2.33% | -3.5% |
| Q4 2017 | $46,367,000 | +81.6% | 1,226,000 | +19.0% | 2.42% | +67.0% |
| Q3 2017 | $25,534,000 | +20.6% | 1,030,000 | 0.0% | 1.45% | +9.8% |
| Q2 2017 | $21,177,000 | +214.4% | 1,030,000 | +232.3% | 1.32% | +195.5% |
| Q1 2017 | $6,736,000 | – | 310,000 | – | 0.45% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TLP GROUP LLC | 2,904,185 | $43,563,000 | 46.00% |
| Foresite Capital Management II, LLC | 3,967,900 | $59,519,000 | 28.42% |
| Aisling Capital LLC | 2,990,000 | $44,850,000 | 9.24% |
| Foresite Capital Management III, LLC | 935,020 | $14,025,000 | 6.56% |
| Vivo Capital, LLC | 763,009 | $11,445,000 | 3.57% |
| RA Capital Management | 1,292,940 | $19,394,000 | 2.00% |
| Palo Alto Investors LP | 379,727 | $5,696,000 | 0.33% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 418,214 | $6,273,000 | 0.32% |
| EMERALD ADVISERS, LLC | 464,364 | $6,965,000 | 0.31% |
| Rock Springs Capital Management LP | 293,000 | $4,395,000 | 0.28% |